摘要
目的探讨MGMT、XRCC1基因在不同级别脑胶质瘤中的表达及其临床应用.方法采用免疫组织化学技术,检测不同级别脑胶质瘤组织中MGMT、XRCC1的表达情况,分析MGMT、XRCC1与胶质瘤的病理级别的关系.结果 MGMT、XRCC1阳性表达在不同级别胶质瘤之间的差异无统计学意义(P>0.05),MGMT和XRCC1在胶质瘤中的表达也无相关性(P>0.05).结论 MGMT、XRCC1的表达与胶质瘤恶性程度无相关性,测定MGMT、XRCC1的表达水平可为胶质瘤的个性化化疗提供参考依据.
Objective To explore the expressions of MGMT and XRCC1 in human brain gliomas and their clinical application. Methods The expressions of MGMT and XRCC1 in glioma tissues were detected by using immunohistoehemical technique, and their correlations with tumor grade were analyzed. Results There were no statistically significant differences in the expressions of MGMT and XRCC1 in gliomas of different grades （P 〉 0.05） The expressions of MGMT and XRCCI in gliomas were not related （P〉0.05） Conclusion The expressions of MGMT and XRCC1 were not related with the tumor grades, and the determination of the expression levels of MGMT and XRCC1 could provide references for individualized chemotherapy of the gliomas.
出处
《昆明医科大学学报》
CAS
2015年第12期112-116,共5页
Journal of Kunming Medical University
基金
中国金属学会治金医学科研立项项目(2010-915)
